Item request has been placed!

Item request cannot be made.

Processing Request

نتائج البحث

Display Settings

النتائج لكل صفحة: 10

Sort By: Relevance

Filter

فلترة النتائج

Publication : liver international

إعادة تعيين خيارات الفبترة

Item request has been placed!

Item request cannot be made.

Processing Request

Academic Journal

Efficacy and safety of treatment with sofosbuvir/velpatasvir in patients aged 6–18 years with chronic hepatitis C—Results of the PANDAA‐PED study.

Authors : Pokorska‐Śpiewak, Maria^1,2 (AUTHOR) maria.pokorska‐; Talarek, Ewa^1,2 (AUTHOR); Aniszewska, Małgorzata^1,2 (AUTHOR)

Source: Liver International. Sep2023, Vol. 43 Issue 9, p1871-1878. 8p. 1 Diagram, 3 Charts, 1 Graph.

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي

Academic Journal

Glecaprevir/Pibrentasvir is safe and effective in Italian patients with chronic hepatitis C aged 75 years or older: A multicentre study.

Authors : Pugliese, Nicola^1,2 (AUTHOR); Calvaruso, Vincenza³ (AUTHOR); Masarone, Mario⁴ (AUTHOR)

Source: Liver International. Jul2023, Vol. 43 Issue 7, p1440-1445. 6p. 2 Charts, 2 Graphs.

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي

Academic Journal

Impact of direct‐acting antiviral treatment on health utility in patients with chronic hepatitis C in hospital and community settings.

Authors : Wong, William W. L.^1,2,3 (AUTHOR) ; Wong, Josephine² (AUTHOR); Bremner, Karen E.² (AUTHOR)

Source: Liver International. Apr2023, Vol. 43 Issue 4, p805-818. 14p. 8 Charts.

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي

Academic Journal

Patient‐specific genetic factors predict treatment failure in sofosbuvir‐treated patients with chronic hepatitis C.

Authors : Loucks, Catrina M.^1,2,3 (AUTHOR); Lin, Jennifer J.^1,2,4 (AUTHOR); Trueman, Jessica N.^1,2 (AUTHOR)

Source: Liver International. Apr2022, Vol. 42 Issue 4, p796-808. 13p. 2 Charts, 2 Graphs.

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي

Academic Journal

Long‐term follow‐up of diabetic and non‐diabetic patients with chronic hepatitis C successfully treated with direct‐acting antiviral agents.

Authors : Ciancio, Alessia¹ (AUTHOR); Ribaldone, Davide G.¹ (AUTHOR); Dotta, Anna¹ (AUTHOR)

Source: Liver International. Feb2021, Vol. 41 Issue 2, p276-287. 12p. 6 Charts, 2 Graphs.

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي

Academic Journal

Inferior cure rate in pilot study of 4‐week glecaprevir/pibrentasvir treatment with or without ribavirin of chronic hepatitis C.

Authors : Madsen, Lone W.^1,2,3 (AUTHOR) ; Christensen, Peer B.^1,2,3 (AUTHOR); Fahnøe, Ulrik⁴ (AUTHOR)

Source: Liver International. Nov2021, Vol. 41 Issue 11, p2601-2610. 10p. 1 Diagram, 2 Charts, 2 Graphs.

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي

Academic Journal

Effectiveness of direct‐acting antivirals for chronic hepatitis C treatment in migrant and non‐migrant populations in France.

Authors : Djaogol, Tchadine¹ (AUTHOR); Fontaine, Hélène² (AUTHOR); Baudoin, Maël^1,3 (AUTHOR)

Source: Liver International. Oct2021, Vol. 41 Issue 10, p2328-2340. 13p. 1 Diagram, 2 Charts, 1 Graph.

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي

Academic Journal

The health impact of delaying direct‐acting antiviral treatment for chronic hepatitis C: A decision‐analytic approach.

Authors : Erman, Aysegul^1,2 (AUTHOR) ; Wong, William W. L.^2,3 (AUTHOR); Feld, Jordan J.⁴ (AUTHOR)

Source: Liver International. Jan2020, Vol. 40 Issue 1, p51-59. 9p. 1 Diagram, 2 Charts, 1 Graph.

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي

Academic Journal

Factors associated with treatment failure of direct‐acting antivirals for chronic hepatitis C: A real‐world nationwide hepatitis C virus registry programme in Taiwan.

Authors : Chen, Chi‐Yi¹ (AUTHOR); Huang, Chung‐Feng^2,3 (AUTHOR); Cheng, Pin‐Nan⁴ (AUTHOR)

Source: Liver International. Jun2021, Vol. 41 Issue 6, p1265-1277. 13p. 4 Charts, 3 Graphs.

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي

Academic Journal

Sofosbuvir and Velpatasvir combination is safe and effective in treating chronic hepatitis C in end‐stage renal disease on maintenance haemodialysis.

Authors : Taneja, Sunil¹ (AUTHOR); Duseja, Ajay¹ (AUTHOR) ; Mehta, Manu¹ (AUTHOR)

Source: Liver International. Apr2021, Vol. 41 Issue 4, p705-709. 5p. 1 Chart.

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي

نتائج البحث

فلترة النتائج

Efficacy and safety of treatment with sofosbuvir/velpatasvir in patients aged 6–18 years with chronic hepatitis C—Results of the PANDAA‐PED study.

Glecaprevir/Pibrentasvir is safe and effective in Italian patients with chronic hepatitis C aged 75 years or older: A multicentre study.

Impact of direct‐acting antiviral treatment on health utility in patients with chronic hepatitis C in hospital and community settings.

Patient‐specific genetic factors predict treatment failure in sofosbuvir‐treated patients with chronic hepatitis C.

Long‐term follow‐up of diabetic and non‐diabetic patients with chronic hepatitis C successfully treated with direct‐acting antiviral agents.

Inferior cure rate in pilot study of 4‐week glecaprevir/pibrentasvir treatment with or without ribavirin of chronic hepatitis C.

Effectiveness of direct‐acting antivirals for chronic hepatitis C treatment in migrant and non‐migrant populations in France.

The health impact of delaying direct‐acting antiviral treatment for chronic hepatitis C: A decision‐analytic approach.

Factors associated with treatment failure of direct‐acting antivirals for chronic hepatitis C: A real‐world nationwide hepatitis C virus registry programme in Taiwan.

Sofosbuvir and Velpatasvir combination is safe and effective in treating chronic hepatitis C in end‐stage renal disease on maintenance haemodialysis.

اتصل بنا

اتبع